Allon Therapeutics, Inc.

Allon files IND to begin clinical trials for second product AL-208

Published in Mental Health Business Week, July 23rd, 2005

Allon Therapeutics, Inc., (NPC), The Neuro Protection Company, announced it has filed an Investigational New Drug application (IND) with the U.S. Food and Drug Administration (FDA) seeking approval to begin human clinical trials evaluating the company's second product AL-208 as a treatment for the mild cognitive impairment (MCI) associated with cardiac artery bypass surgery.

Gordon McCauley, president and CEO of Allon, said that subject to FDA approval, the company will commence a phase I clinical trial during Q3 2005 evaluating the safety, tolerability, and pharmacokinetics of AL-208 in healthy adults. The company expects the phase I trials to be complete in Q4 2005...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Mental Health Business Week

Source: Mental Health Business Week (2005-07-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry